Trial intelligence / Profile preview

Dose-finding crossover study of oromucosal physostigmine for chronic dry mouth

2005-006017-41Phase 2Completed

Sponsor: Calabar Pharmaceutical Company
Start: Dec 2005
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised, double-blind trial of physostigmine in xerostomia, sponsored by Calabar Pharmaceutical Company. Primary endpoints: Subjective mouth dryness, Subjective taste perception and 1 more. Started Dec 2005; status: completed.

Drugs

physostigmine

Conditions

xerostomia

Beyond the preview

Go deeper on 2005-006017-41.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-006017-41.